CYP2D6 genotype and smoking behaviour in cigarette smokers

Pharmacogenetics

Volumn 7, Issue 5, 1997, Pages 411-414

  Boustead, Carol ^a   Taber, Heather ^a   Idle, Jeffrey R ^b   Cholerton, Suzanne ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Cigarette smoking; CYP2D6; Genotype

Indexed keywords

CYTOCHROME P450;

ADULT; ALLELE; BEHAVIOR; CIGARETTE SMOKING; CLINICAL TRIAL; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SHORT SURVEY; SMOKING;

CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS; MIDDLE AGED; PLANTS, TOXIC; SMOKING; TOBACCO; TOBACCO USE DISORDER;

EID: 0030858061     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199710000-00012     Document Type: Short Survey

References (14)

1. Benowitz NL, Kuyt F, Jacob P III. Circadian blood nicotine concentrations during cigarette smoking. Clin Pharmacol Ther 1982: 32, 758-764
2. Benowitz NL, Jacob P, III, Sachs DPL. Deficient C-oxidation of nicotine. Clin Pharmacol Ther 1995: 57, 590-594.
3. Benowitz NL, Jacob P III, Perez-Stable E. CYP2D6 phenotype and the metabolism of nicotine and cotinine. Pharmacogenetics 1996: 6, 239-242.
4. Bertilsson L, Alm C, De Las Carrerras C, Widen J, Edman G, Schalling D. Debrisoquine hydroxylation polymorphism and personality. Lancet 1989: 1, 555.
5. Cholerton S, Arpanahi A, McCracken N, Boustead C, Taber H, Johnstone E, Leathart J, Daly AK, Idle JR. Poor metabolisers of nicotine and CYP2D6 polymorphism. Lancet 1994: 343, 62-63.
6. Cholerton S, Boustead C, Taber H, Arpanahi A, Idle JR. CYP2D6 genotypes in cigarette smokers and non-tobacco users. Pharmacogenetics 1996: 6, 261-263.
7. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1991: 1, 33-41.
8. Fagerstrom KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 1978: 3, 235-241.
9. Fagerstrom KO, Schneider NG. Measuring nicotine dependence: A review of the Fagerstrom Tolerance Questionnaire. J Behav Med 1989: 12, 159-183.
10. Llerena A, Edman G, Cobaleda J, Benitez J, Schalling D, Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Acta Psychiat Scand 1993: 87, 23-28.
11. Pomerleau CS, Carton SM, Lutzke ML, Flessland KA, Pomerleau OF. Reliability of the Fagerstrom Tolerance Questionnaire and the Fagerstrom Test for Nicotince Dependence. Addict Behav 1994: 19, 33-39.
12. Russell MAH, Peto J, Patel UA. The classification of smoking by factorial structure of motives. J Roy Stat Soc Ass 1974: 137, 313-334.
13. Tefre T, Daly AK, Armstrong M, Leathart LBS, Idle JR, Brogger A, Borresen A-L. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics 1994: 4, 47-57.
14. West RJ, Russell MAH. Pre-abstinence smoke intake and smoking motivation as predictors of severity of cigarette withdrawal symptoms. Psychopharmacol 1985: 87, 334-336.